ample, if there is comorbid phencyclidine-induced psychotic disorder, only the phencyclidine-
induced psychotic disorder code is given, with the 4th character indicating whether the co-
morbid phencyclidine use disorder is mild, moderate, or severe: F16.159 for mild phencycli-
dine use disorder with phencyclidine-induced psyc hotic disorder or F16.259 for a moderate
or severe phencyclidine use disorder with phencyclidine-induced psychotic disorder.
Specify current severity:
305.90 (F16.10) Mild:  Presence of 2–3 symptoms.
304.60 (F16.20) Moderate: Presence of 4–5 symptoms.
304.60 (F16.20) Severe:  Presence of 6 or more symptoms.
Specifiers
“In a controlled environment” app lies as a further specifier of remission if the individual is
both in remission and in a controlled environm ent (i.e., in early remission in a controlled
environment or in sustained remission in a controlled environment). Examples of these
environments are closely supe rvised and substanc e-free jails, therapeutic communities,
and locked hospital units. 
Diagnostic Features
The phencyclidines (or phencyclidine-like substances) include phencyclidine (e.g., PCP,
“angel dust”) and less potent but similarly ac ting compounds such as ketamine, cyclohex-
amine, and dizocilpine. These substances were  first developed as dissociative anesthetics
in the 1950s and became street drugs in the 1960s. They produce feelings of separation
from mind and body (hence “d issociative”) in low doses, an d at high doses, stupor and